AR002707A1 - THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES. - Google Patents

THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES.

Info

Publication number
AR002707A1
AR002707A1 ARP960101382A AR10138296A AR002707A1 AR 002707 A1 AR002707 A1 AR 002707A1 AR P960101382 A ARP960101382 A AR P960101382A AR 10138296 A AR10138296 A AR 10138296A AR 002707 A1 AR002707 A1 AR 002707A1
Authority
AR
Argentina
Prior art keywords
vertebral
fractures
reduce
alendronate
novertebral
Prior art date
Application number
ARP960101382A
Other languages
Spanish (es)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/389,860 external-priority patent/US20010051616A1/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR002707A1 publication Critical patent/AR002707A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cuando se administra diariamente por un período de tiempo substancial, el alendronato, un bisfosfonato, puede reducir la tasa de fracturas vertebrales yno- vertebrales en mujeres post-menopáusicas. Además, puede reducir el número y severidad delas fracturas. También, la administración de aledronato puedeprevenir la deformación columnar y la pérdida de altura.When administered daily for a substantial period of time, alendronate, a bisphosphonate, can reduce the rate of vertebral and non-vertebral fractures in postmenopausal women. In addition, it can reduce the number and severity of fractures. Also, the administration of aledronate can prevent columnar deformation and loss of height.

ARP960101382A 1995-02-17 1996-02-14 THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES. AR002707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39046295A 1995-02-17 1995-02-17
US08/389,860 US20010051616A1 (en) 1995-02-17 1995-02-17 Method of lessening the risk of vertebral fractures
US41963195A 1995-04-10 1995-04-10

Publications (1)

Publication Number Publication Date
AR002707A1 true AR002707A1 (en) 1998-04-29

Family

ID=27409915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101382A AR002707A1 (en) 1995-02-17 1996-02-14 THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES.

Country Status (9)

Country Link
AR (1) AR002707A1 (en)
CO (1) CO4920257A1 (en)
CZ (1) CZ259097A3 (en)
DZ (1) DZ1991A1 (en)
HR (1) HRP960080A2 (en)
IL (1) IL117077A (en)
PE (1) PE46197A1 (en)
TW (1) TW453880B (en)
YU (1) YU8896A (en)

Also Published As

Publication number Publication date
IL117077A0 (en) 1996-06-18
IL117077A (en) 2002-08-14
YU8896A (en) 1999-12-27
TW453880B (en) 2001-09-11
PE46197A1 (en) 1997-11-28
HRP960080A2 (en) 1997-10-31
DZ1991A1 (en) 2002-07-20
CZ259097A3 (en) 1997-11-12
CO4920257A1 (en) 2000-05-29

Similar Documents

Publication Publication Date Title
MY100721A (en) Therapeutic agent.
ITRM930591A0 (en) MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR DRUGS AT VERY LOW DOSES, IN PARTICULAR HOMEOPATHIC DRUGS.
AU4449789A (en) Delivery system for pharmaceutical or therapeutic actives
ES2190244T3 (en) USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES.
BR9609645A (en) Inhaler for drug administration from ampoule packs
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
ATE231719T1 (en) NEW PHARMACEUTICAL FORMULATIONS
HUP0001914A3 (en) Biocompatible compounds for pharmaceutical drug delivery systems
RU94032150A (en) Medicinal agent exhibiting delayed release of active-acting substance
ES554169A0 (en) METHOD OF MANUFACTURING A MEDICAL DEVICE FOR THE ADMINISTRATION OF A FAT-INSOLUBLE, HIGHLY IONIZED DRUG.
IS2537B (en) Medicinal product for intravenous administration
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
AU2084801A (en) Antiviral medication
ES2159362T3 (en) USE OF 1- (2-NAFT-2-ILETIL) -4- (3-TRIFLUOROMETILFENIL) -1,2,3,6-TETRAHYDROPIRIDINE FOR THE PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS.
ES2010466A6 (en) Effervescent tablet containing diclofenac
AR002707A1 (en) THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES.
BR9608392A (en) Multiparticulate controlled-release preparation and tablet dosage form.
AR011437A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MIGRANES AND THE USE OF THE SAME IN THE PREPARATION OF A MEDICINAL PRODUCT.
ATE150004T1 (en) TILIDINE DIHYDROGEN ORTHOPHOSPHATE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
ZA963714B (en) Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours.
ATE234096T1 (en) PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION CONTAINING THE ACTIVE INGREDIENT MORPHINE-6-GLUCURONIDE
ES2152865A1 (en) Use of bisphosphonates in pharmaceutical preparations intended for intramuscular use
PT1144420E (en) PHOSPHATIDILINOSITOIS SULPHATATED TO ITS PREPARATION AND ITS UTILIZATION
ECSP961665A (en) METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES
AU5981200A (en) Transdermal therapeutic system for administering a calcium antagonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal